Idenix Pharma Will Cease IDX 184, IDX 19368

Shares of Idenix Pharma

were halted during after-hours trading Monday. The company announced that it has "elected not to continue its clinical development program" for IDX184. In addition, it will not continue its development of IDX19368. The company cites a decision by the FDA to keep the IDX184 and IDX19368 programs on clinical hold. Due to this decision, Idenix Pharma has elected to cease the development.